PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

Bayer

Status: Completed

Conditions: Diagnostic Imaging

Treatments: Drug: Ultravist (Iopromide, BAY86-4877)

Study type: Observational

Funder types: Industry

Identifiers

NCT00876083

13276

14480

14376

13422

14181

UV0701

14692

14337

13859

14338

14527

14586

13421

13275

14243

14661

14528

14336

14245

14180

13212

14526

13602

Details and patient eligibility

About

The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.

Enrollment: 44,920 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Exclusion criteria

• No exclusion criteria besides the contraindications for the use of Ultravist as mentioned in the product information.

Trial design

44,920 participants in 1 patient group

Group 1

Treatment:

Drug: Ultravist (Iopromide, BAY86-4877)